- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02637648
Sodium Oxybate in Patients With Episodic and Chronic Cluster Headache (SOinCH)
December 18, 2015 updated by: Ramin Khatami
Safety and Efficacy of Sodium Oxybate in the Prophylaxis of Headache and Sleep Disturbances in Patients With Chronic and Episodic Cluster Headache
The purpose of this study is to test the effects of sodium oxybate on headache response (frequency), sleep quality and quality of life in the prophylactic treatment of patients with chronic and episodic cluster headache.
Oral sodium oxybate, 3-9g per night, starting with 3g in two nightly dosages of 1.5g and increased by steps of 1.5g every second or third night until treatment Response will be evaluated in an interventional, placebo-controlled, double-blind, randomised, parallel group, multicentre study.
Primary outcome is reduction of nocturnal pain frequency Secondary outcomes are improvement of sleep quality at a subjective level as assessed by diary and standardized scales (PSQI, FOSQ), duration of pain free episodes, general clinical outcome (global evaluation), clinical global impression (CGI-S, CGI-I, CGI-E), quality of life (SF 36) and daytime sleepiness (Epworth Sleepiness Score).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Multicenter study to test the safety and efficacy of sodium oxybate in the prophylaxis of headache and sleep disturbances in patients with chronic and episodic cluster headache using a placebo-controlled, double blind, randomized study, parallel group design.
Patients with predominant nocturnal attacks and poor sleep quality will be evaluated; At least 1 attack every other day and at least 8 attacks cumulatively by the time prior to randomization are required.
Sodium oxybate will be orally administered, 3-9g per night, starting with 3g in two nightly dosages of 1.5g (the first at bedtime and the second 4 hours later).
Dosage will be gradually increased by steps of 1.5g every second night until treatment response during a titration period of 14 days.
Effects od sodium oxybate will be monitored via pain and sleep diaries during a 14 days stable treatment phase by reviewing sleep/pain diaries and Quality of life assessement.
Primary outcomes are frequency of nocturnal pain attacks; Main secondary outcomes are frequency, intensity and duration of daytime pain attacks, improvement of sleep quality, quality of life, duration and rates of pain free episodes, decrease in escape medication for acute headache attacks (use of triptans).
Safety parameters are ECG, laboratory, depressions scales, vital signs, respiratory polygraphy.
Intent-to treat analysis, multivariate analysis of variance (MANOVA) with depending variable (reduction of pain frequency and pain intensity of nocturnal attacks) and the co-variates (age, sex , chronic vs. episodic CH).
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ramin Khatami, MD
- Phone Number: +41 62 857 2220
- Email: ramin.khatami@barmelweid.ch
Study Contact Backup
- Name: Sabine Studer
- Phone Number: +41 62 857 2228
- Email: sabine.studer@barmelweid.ch
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Current diagnosis of cluster headache according to the criteria of International Headache Classification (ICHD-II, 2005) of the International Headache Society (IHS).
- Diagnosis of cluster headache has been made at least 6 weeks after start of screening
- Patients will have nocturnal pain attacks
- Duration since onset of current cluster episode at least 1 week
- Patients will have at least 1 attack per 48 hours and at least 4 attacks cumulatively by the time of visit 2 (prior to randomization)
- Disturbed sleep quality
- Patients have expressed a willingness to participate in and complete the study, and signed and dated informed consent prior to beginning protocol required procedures.
- Women must be surgically sterile or 2 years postmenopausal. Females of child-bearing potential must use a medically accepted effective method of birth control. Patients should agree to continue this method for the duration of the study and for one month after the discontinuation of SO treatment. Women should be negative to serum pregnancy test performed at the screening visit. Females should not be breastfeeding patient.
- In the opinion of the investigator, the patient must have adequate support to comply with the entire study requirements as described in the protocol (e.g., transportation to and from trial site, self rating scales and diaries completion, drug compliance, scheduled visits, tests).
- If indicated by investigator, patient must be willing to not operate a car or heavy machinery for 6 hours after the last intake of the investigational drug during the duration of the trial or as long as the investigator deems clinically indicated. In addition, the patient should be willing to abstain during the study any alcohol consumption or behaviours which could interact with the investigational drug.
Exclusion Criteria:
- The use of sodium oxybate or any previous investigational drugs within 30-day period prior to initial screening visit (V1) for this trial.
- Change of prophylactic treatment 2 weeks prior of baseline visit 1
- Have sleep apnea syndrome, defined as an Apnea index > 10 per hour or an Apnea-hypopnea Index (AHI) > 15/h or an oxygen desaturation index (ODI) > 15/h
- Are taking hypnotics, tranquilizers, antihistamines (except for medication as defined in section 9.4.1. "authorized medication"), benzodiazepines at the start of the baseline period.
- Patients with psychiatric and neurological disorders, such as moderate or severe psychosis or dementia, bipolar illness, severe anxiety, clinical depression (BDI ≥ 16 with suicidal risk: item G BDI >0).
- Patients who are experiencing any major illness, including unstable cardiovascular, endocrine, neoplastic, gastrointestinal, hematologic, hepatic, immunologic, metabolic, neurological, pulmonary, and/or renal disease which would place the patient at risk during the trial or compromise the objectives outlined in the protocol.
- Patients who are unable or unwilling to temporarily discontinue any unauthorized drugs or substances, in particular refrain from alcohol (see section non-authorized treatments).
- Current or recent (within one year) history of a substance abuse or dependence disorder including alcohol abuse as defined in Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
- Patients taking anticonvulsants are not eligible to participate even if they are willing to washout anticonvulsants for the trial.
- Patients having other problems that, in the investigators opinion, would preclude the patient's participation and completion of this trial or compromise reliable representation of subjective symptoms.
- Patients having a history of seizure disorder
- Patients having a severe renal impairment (e.g. serum creatine greater than 2.0 mg/dl), or a with severe hepatic impairment (abnormal liver function tests SGOT [AST] or SGPT [ALT] more than twice of the upper limit of normal) or elevated serum bilirubin (more than 1.5 times the upper limit of normal) or receiving anti-vitamin K substances.
Any significant serious abnormality of the cardiovascular system e.g. recent myocardial infarction, angina, hypertension or dysrhythmias (within the prior 6 months), greater than a first degree AV block.
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sodium oxbate
oral administration of sodium oxybate, 6-18ml per night, starting with 6ml in two nightly dosages of 1.5g each, increased by steps of 1.5g every second or third night until treatment response
|
parallel Group administration
Other Names:
|
Placebo Comparator: Placebo
oral administration of placebo, 6-18ml per night, starting with 6ml in two nightly dosages
|
parallel Group administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
nocturnal pain frequency as assessed by patients reports
Time Frame: 4 weeks
|
Reduction of nocturnal pain frequency as documented in patients diary,
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of sleep quality
Time Frame: 4 weeks
|
Change assessed by PSQI (Pittsburgh Sleep Quality Inventory)
|
4 weeks
|
pain free time as assessed by diary
Time Frame: 4 weeks
|
number and duration of pain free time periods compared to baseline
|
4 weeks
|
Clinical Global Impression
Time Frame: 4 weeks
|
Change assessed by CGI-E scale
|
4 weeks
|
Quality of life
Time Frame: through study completion
|
Assessed by SF 36
|
through study completion
|
Daytime Sleepiness
Time Frame: 4 weeks
|
Improvement as assessed by Epworth Sleepiness Score
|
4 weeks
|
Escape medication
Time Frame: 4 weeks
|
Decrease in escape medication for acute headache attacks (use of triptans)
|
4 weeks
|
Depression
Time Frame: 4 weeks
|
Change in Beck's depression inventory (BDI-II)
|
4 weeks
|
Functional outcome of sleep quality
Time Frame: 4 weeks
|
Changes as assessed by questionaire of Functional Outcomes of Sleep Questionaire (FOSQ)
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ramin Khatami, MD, Clinic Barmelweid AG
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2015
Primary Completion (Anticipated)
September 1, 2016
Study Completion (Anticipated)
June 1, 2017
Study Registration Dates
First Submitted
December 9, 2015
First Submitted That Met QC Criteria
December 18, 2015
First Posted (Estimate)
December 22, 2015
Study Record Updates
Last Update Posted (Estimate)
December 22, 2015
Last Update Submitted That Met QC Criteria
December 18, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Headache Disorders, Primary
- Headache Disorders
- Trigeminal Autonomic Cephalalgias
- Headache
- Cluster Headache
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Adjuvants, Anesthesia
- Sodium Oxybate
Other Study ID Numbers
- BWSO0812
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cluster Headache
-
Diamond Headache ClinicGlaxoSmithKlineUnknownEpisodic Cluster Headache | Chronic Cluster HeadacheUnited States
-
Eli Lilly and CompanyCompletedEpisodic Cluster Headache | Chronic Cluster HeadacheSpain, United States, Finland, Germany, United Kingdom, Belgium, France, Denmark, Italy, Netherlands, Canada, Greece
-
Winston LaboratoriesNot yet recruitingEpisodic Cluster Headache
-
Man and Science, SARecruitingChronic Cluster HeadacheBelgium
-
Radboud University Medical CenterLeiden University Medical Center; ZonMw: The Netherlands Organisation for Health... and other collaboratorsNot yet recruitingChronic Cluster Headache
-
Leiden University Medical CenterUniversity of Copenhagen; Maastricht University Medical Center; Erasmus Medical... and other collaboratorsCompletedChronic Cluster HeadacheNetherlands, Belgium, Germany, Hungary
-
Hospices Civils de LyonNot yet recruitingCluster Headache, Episodic
-
H. Lundbeck A/SCompletedCluster Headache, EpisodicSpain, United States, Germany, Portugal, Italy, Netherlands, Finland, Belgium, Czechia, Denmark, France, Georgia, Russian Federation, United Kingdom, Greece, Estonia, Japan, Norway, Sweden
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedEpisodic Cluster HeadacheUnited States, Australia, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom, Canada
-
Eli Lilly and CompanyCompletedEpisodic Cluster HeadacheItaly, United States, Canada, Belgium, Denmark, Finland, France, Germany, Spain, United Kingdom, Netherlands, Greece
Clinical Trials on Sodium Oxybate
-
Jazz PharmaceuticalsCompleted
-
Kristina SimonyanNational Institutes of Health (NIH); National Institute on Deafness and Other...CompletedSpasmodic Dysphonia | Voice TremorUnited States
-
University Hospital, GhentUCB PharmaWithdrawn
-
Baylor College of MedicineJazz PharmaceuticalsCompleted
-
St. Luke's Hospital, Chesterfield, MissouriJazz PharmaceuticalsCompleted
-
Orphan MedicalCompletedNarcolepsyUnited States, Canada, Switzerland
-
Jazz PharmaceuticalsCompleted
-
Tufts Medical CenterWithdrawnMechanically Ventilated ICU PatientsUnited States
-
UCB Pharma SACompletedNarcolepsy With CataplexyBelgium
-
National Center for Complementary and Integrative...CompletedHot Flashes | Osteoporosis, Postmenopausal | PostmenopauseUnited States